Future clinical trials in DIPG: Bringing epigenetics to the clinic

Frontiers in Oncology

Volumn 5, Issue JUL, 2015, Pages

  La Madrid, Andres Morales ^a   Hashizume, Rintaro ^b   Kieran, Mark W ^c,d  

^a HOSPITAL SANT JOAN DE DÉU   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Children; Clinical trials; DIPG; Epigenetics

Indexed keywords

EID: 84934291901     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00148     Document Type: Short Survey

References (30)

1. Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol (2014) 119(1):7-15. doi:10.1007/s11060-014-1448-8.
2. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol (2012) 28(2):205. doi:10.3389/fonc.2012.00205.
3. Roos DE, Smith JG. Randomized trial on radiotherapy for paediatric diffuse intrinsic pontine glioma (DIPG). Radiother Oncol (2014) 113(3):425. doi:10.1016/j.radonc.2014.08.041.
4. Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol (2012) 35(1):51-7. doi:10.1097/COC.0b013e318201a2b7.
5. Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJL. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev (2012) 38(1):27-35. doi:10.1016/j.ctrv.2011.06.007.
6. Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A (2011) 108(11):4453-8. doi:10.1073/pnas.1101657108.
7. Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet (2014) 46(5):451-6. doi:10.1038/ng.2936.
8. Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol (2014) 128(4):573-81. doi:10.1007/s00401-014-1319-6.
9. Roujeau T, Machado G, Garnett MR, Miquel C, Puget S, Geoerger B, et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg (2007) 107(1 Suppl):1-4.
10. Puget BS, Blauwblomme T, Grill J. Is biopsy safe in children with newly diagnosed diffuse intrinsic pontine glioma? Am Soc Clin Oncol Educ Book (2012):629-33. doi:10.14694/EdBook_AM.2012.32.629.
11. Waldmann T, Schneider R. Targeting histone modifications - epigenetics in cancer. Curr Opin Cell Biol (2013) 25(2):184-9. doi:10.1016/j.ceb.2013.01.001.
12. Khuong-Quang D-A, Buczkowicz P, Rakopoulos P, Liu X-Y, Fontebasso AM, Bouffet E, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol (2012) 124(3):439-47. doi:10.1007/s00401-012-0998-0.
13. Becher BOJ, Wechsler-Reya RJ. For pediatric glioma, leave no histone unturned. Science (2014) 346:1458. doi:10.1126/science.aaa3814.
14. Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset P-O, et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet (2014) 46(5):462-6. doi:10.1038/ng.2950.
15. Taylor KR, Mackay A, Truffaux N, Butterfield YS, Morozova O, Philippe C, et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet (2014) 46(5):457-61. doi:10.1038/ng.2925.
16. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y, et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet (2014) 46(5):444-50. doi:10.1038/ng.2938.
17. Grill J, Puget S, Andreiuolo F, Philippe C, MacConaill L, Kieran M. Critical oncogenic mutations in newly diagnosed pedriatic diffuse intrinsic pontine glioma. Pediatr Blood Cancer (2012) 58:489-91. doi:10.1002/pbc.24060.
18. Bechet D, Gielen GGH, Korshunov A, Pfister SM, Rousso C, Faury D, et al. Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol (2014) 128:733-41. doi:10.1007/s00401-014-1337-4.
19. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell (2012) 150(1):12-27. doi:10.1016/j.cell.2012.06.013.
20. Ahsan S, Raabe EH, Haffner MC, Vaghasia A, Warren KE, Quezado M, et al. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun (2014) 2:59. doi:10.1186/2051-5960-2-59.
21. Banaszynski LA, Garcia BA, Muir TW, Becher OJ, Allis CD. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science (2013) 340:857-61. doi:10.1126/science.1232245.
22. Lewis PW, Allis CD. Poisoning the "histone code" in pediatric gliomagenesis. Cell Cycle (2013) 12(20):3241-2. doi:10.4161/cc.26356.
23. Funato K, Major T, Lewis PW, Allis CD, Tabar V. Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation. Science (2014) 346(6216):1529-33. doi:10.1126/science.1253799.
24. Hashizume R, Andor N, Ihara Y, Lerner R, Gan H, Chen X, et al. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat Med (2014) 20(12):1394-6. doi:10.1038/nm.3716.
25. Ramaswamy V, Remke M, Taylor MD. An epigenetic therapy for diffuse intrinsic pontine gliomas. Nat Med (2014) 20(12):1378-9. doi:10.1038/nm.3769.
26. Ntziachristos P, Tsirigos A, Welstead GG, Trimarchi T, Bakogianni S, Xu L, et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature (2014) 514(7523):513-7. doi:10.1038/nature13605.
27. Grasso CS, Tang Y, Truffaux N, Berlow NE, Liu L, Debily M-A, et al. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat Med (2015) 21(6):555-9. doi:10.1038/nm.3855.
28. Wolff JE, Rytting ME, Vats TS, Zage PE, Ater JL, Woo S, et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience. J Neurooncol (2012) 106(2):391-7. doi:10.1007/s11060-011-0677-3.
29. Riviere M-K, Le Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann Oncol (2014) 26(4):669-74. doi:10.1093/annonc/mdu516.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144(5):646-74. doi:10.1016/j.cell.2011.02.013.